NCT05202301 - A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely | Biotech Hunter

Enrollment

13,779

Participants

Timeline

Start Date

January 15, 2022

Primary Completion Date

July 15, 2025

Study Completion Date

July 15, 2025

Conditions

Prostate Cancer

Interventions

DRUG

Darolutamide (Nubeqa, BAY1841788)

Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database

DRUG

Enzalutamide

Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database

DRUG

Apalutamide

Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database

Trial Locations (1)

Bayer, Whippany